Journal of the American College of Cardiology Vol. 36, No. 2, by the American College of Cardiology ISSN /00/$20.

Size: px
Start display at page:

Download "Journal of the American College of Cardiology Vol. 36, No. 2, by the American College of Cardiology ISSN /00/$20."

Transcription

1 Journal of the American College of Cardiology Vol. 36, No. 2, by the American College of Cardiology ISSN /00/$20.00 Published by Elsevier Science Inc. PII S (00) Randomized, Placebo-Controlled Trial of the Angiotensin-Converting Enzyme Inhibitor, Ramipril, in Patients With Coronary or Other Occlusive Arterial Disease Stephen MacMahon, PHD, MPH, FACC,* Norman Sharpe, MD, FRACP, FACC, Greg Gamble, MSC, Alison Clague, RN, Cliona Ni Mhurchu, PHD, Taane Clark, MSC, Hamish Hart, MB, CHB, FRACP, John Scott, MD, FRACP, Harvey White, DSC, FRACP, FACC, for the PART-2 Collaborative Research Group Sydney, Australia and Auckland, New Zealand OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS The primary objective of this study was to investigate the effects of the angiotensin-converting enzyme (ACE) inhibitor, ramipril, on carotid atherosclerosis in patients with coronary, cerebrovascular or peripheral vascular disease. Angiotensin-converting enzyme inhibitors have been shown to reduce the risk of coronary events in various patient groups and to prevent the development of atherosclerosis in animal models. It has been hypothesized that the clinical benefits of ACE inhibitors may, therefore, be mediated by effects on atherosclerosis. Six hundred seventeen patients were randomized in equal proportions to ramipril (5 10 mg daily) or placebo. At baseline, two years and four years, carotid atherosclerosis was assessed by B-mode ultrasound, and left ventricular mass was assessed by M-mode echocardiography. Blood pressure (BP) was reduced by a mean of 6 mm Hg systolic and 4 mm Hg diastolic in the ramipril group compared with the placebo group (p 0.001). There was no difference between groups in the changes in common carotid artery wall thickness (p 0.58) or in carotid plaque (p 0.93). Left ventricular mass index decreased by 3.8 g/m 2 (4%) in the ramipril group compared with the placebo group (2p 0.04). The results provide no support for the hypothesis that reduced atherosclerosis is responsible for the beneficial effects of ACE inhibitors on major coronary events. It is more likely that the benefits are due to lower BP, reduced left ventricular mass or other factors such as reversal of endothelial dysfunction. (J Am Coll Cardiol 2000;36:438 43) 2000 by the American College of Cardiology Among patients with heart failure or left ventricular dysfunction, long-term treatment with angiotensin-converting enzyme (ACE) inhibitors has been shown to reduce the risk of major coronary events (1) as well as the risks of cardiovascular death and heart failure related morbidity (2). A recent report from the Heart Outcomes Prevention Evaluation (HOPE) Study (3) indicates that these benefits extend to a variety of other patient groups without impaired left ventricular (LV) function but at high risk for coronary events. It has been suggested that the effects of ACE inhibitors on coronary events may be mediated by unique vascular protective effects that involve the regression or prevention of atherosclerosis (4). This hypothesis was based primarily on the evidence of anti-atherosclerotic and antiproliferative effects of ACE inhibitors in animal models (5 8). However, there is little direct evidence about the From the *Institute for International Health and Department of Medicine, University of Sydney, Sydney, Australia; Department of Medicine, University of Auckland, Auckland, New Zealand; Clinical Trials Research Unit, University of Auckland, Auckland, New Zealand; Department of Medicine, North Shore Hospital, Auckland, New Zealand; Department of Medicine, University of Auckland, Auckland, New Zealand; Coronary Care and Cardiovascular Research Units, Greenlane Hospital, Auckland, New Zealand. The Prevention of Atherosclerosis with Ramipril (PART 2) trial was supported by a project grant from Hoechst AG, the manufacturers of ramipril and by a program grant from the Health Research Council of New Zealand. Manuscript received October 20, 1999; revised manuscript received January 26, 2000, accepted March 29, effects of ACE inhibitors on atherosclerosis in man. This study was conducted to determine the effects of the ACE inhibitor, ramipril, on carotid atherosclerosis and other outcomes, including LV hypertrophy, in patients with a history of coronary or other occlusive arterial disease. METHODS Patients. The study participants were recruited from four collaborating centers in metropolitan Auckland: the Auckland, Green Lane, Middlemore and North Shore Hospitals. Approval for the conduct of the study in each of these institutions was provided by the Auckland Regional Ethics Committee. Patients aged 75 years or younger who provided written informed consent to participate were eligible for inclusion if they had a hospital diagnosis (within five years of enrollment) of any of the following: acute myocardial infarction (MI), angina with coronary disease confirmed by angiography or exercise electrocardiogram, transient ischemic attack (TIA) or intermittent claudication. Individuals were not eligible if they had congestive heart failure (CHF) or any other definite indication for treatment with an ACE inhibitor, a contraindication to treatment with an ACE inhibitor, serious nonvascular disease, a diastolic blood pressure (BP) 100 mm Hg, a systolic BP 160 mm Hg or 100 mm Hg during the

2 JACC Vol. 36, No. 2, 2000 August 2000: MacMahon et al. Ramipril and Atherosclerosis 439 Abbreviations and Acronyms ACE angiotensin-converting enzyme BP blood pressure CHF congestive heart failure HOPE Heart Outcomes Prevention Evaluation LV left ventricle (left ventricular) MI myocardial infarction TIA transient ischemic attack prerandomization run-in period, or were of childbearing potential without adequate contraception. Design and study treatment. Prior to randomization, potentially eligible patients entered a two-week tolerability phase during which they received ramipril 5 mg daily for the first week and ramipril 10 mg daily for the second week. The purpose of this open-treatment phase was to identify patients who could not tolerate even a short course of treatment with ramipril or who were unlikely to comply with treatment or follow-up procedures. Those compliant patients who tolerated at least 5 mg ramipril daily were then randomized to continue active treatment or to receive placebo in a double-blind, parallel-group design. Depending on the outcome in the tolerability phase, patients received either 5 mg or 10 mg ramipril once daily or matching placebo. Treatment assignment was obtained by telephone call to the Clinical Trials Research Unit randomization service in Auckland. Randomization was performed by computer using a minimization algorithm that balanced treatment assignment by center, disease inclusion criteria and current use of a beta-adrenergic blocking agent. The double-blind treatment and follow-up phase was scheduled to continue for a minimum of four years, during which patients were seen at three monthly clinic visits throughout. Study outcomes. At baseline, two years and four years, B-mode ultrasound recordings of the carotid arteries and M-mode echocardiograms were performed in the Cardiovascular Research Laboratory of the University of Auckland Department of Medicine. Ultrasound images of common and internal carotid arteries were captured with an Acuson 128 ultrasound machine and 10-MHz linear transducer (Mountainview, California). Images were digitized and stored for off-line analysis. For each patient, three views of the right and left common carotid arteries were collected, maximizing the lumen diameter to ensure that the plane of interrogation was orthogonal to the artery wall. All discrete plaques ( 1.2 mm in height) in the internal, external and common carotid arteries and bulb were also recorded. Three ultrasonographers, blind to study treatment allocation, performed all examinations using a standardized protocol. The images collected at baseline, two and four years were measured at the end of the study by an ultrasonographer and a radiologist blind to study treatment allocation but not to the order of scans. Throughout the measurement period, checks were conducted to assess the reliability of the measurements obtained. Measurements of carotid artery far wall thickness and lumen diameter were made on a 1 cm length of the right and left common carotid artery immediately proximal to the bulb, using methods described previously (9). This method of estimating carotid far wall thickness is reproducible (limits of agreement 8%) and has previously been shown to closely resemble total carotid wall thickness measured histologically (10). Mean carotid artery far wall thickness was prespecified as the primary study outcome. Discrete plaques (as defined above) in the internal, external and common carotid arteries and bulb were identified, and the sum of the heights of all such plaques in the entire carotid tree on both the left and right sides was calculated for each patient (carotid plaque score). Left ventricular dimensions were measured using twodimensionally guided M-mode echocardiography. An M-mode view of the LV from the parasternal long axis with the M-mode cursor perpendicular to both the LV septum and posterior wall at the level of the mitral valve chordae was recorded, and LV mass was determined using the American Society of Echocardiography modified Penn convention. The LV mass index was calculated as LV mass (g) divided by body surface area (m 2 ). Throughout follow-up, systolic and diastolic BPs were measured in duplicate at every clinic visit using a standard mercury sphygmomanometer, following a standardized protocol. Details of all clinical events resulting in death, hospitalization or withdrawal from study treatment were also recorded throughout follow-up. Statistical methods. The study sample size was calculated to provide 80% power (with p 0.05) to detect a 0.05 mm difference between groups in the primary study outcome, mean carotid artery far wall thickness. All outcome analyses were conducted according to the intention-to-treat principle. The effect of treatment on all continuous outcome variables was tested using analysis of variance to estimate main and interaction effects for repeated observations over time. A maximum likelihood approach was used to impute missing at-random data within this model. The variables used in the minimization algorithm to balance the groups at randomization were included as terms in the model. Post hoc tests of significant main and interaction effects were performed using the methods of Tukey. The same methods were used to test differences between randomized groups in the change in other carotid artery measurements, LV mass and BP levels during follow-up. All p values were calculated from two-tailed tests of statistical significance. A 5% significance level was maintained throughout these analyses. Relative risk of major nonfatal and fatal events was estimated using Cox proportional hazards models adjusted for the variables used in the minimization algorithm. The frequency of hospital admissions was analyzed using chisquare tests. The study was not designed to determine the effects of treatment on mortality or morbidity, but analyses were prespecified for the following clinical outcomes: total cardiovascular events (death from cardiovascular disease or hospitalization for MI, unstable angina, stroke or CHF),

3 440 MacMahon et al. JACC Vol. 36, No. 2, 2000 Ramipril and Atherosclerosis August 2000: Table 1. Baseline Characteristics of Randomized Patients major coronary events (death from coronary heart disease or hospitalization for nonfatal MI), death from cardiovascular disease, total mortality and total hospital admissions. RESULTS Ramipril (n 308) Placebo (n 309) Mean (SD) or % Risk factors Age (years) 60 (8) 61 (8) Men % Systolic blood pressure (mm Hg) 133 (17) 133 (16) Diastolic blood pressure (mm Hg) 79 (9) 79 (10) Total cholesterol (mmol/l) 6.2 (1.1) 6.1 (1.0) HDL cholesterol (mmol/l) 1.2 (0.3) 1.1 (0.3) LDL cholesterol (mmol/l) 4.2 (1.0) 4.1 (0.9) Triglycerides (mmol/l) 1.8 (1.2) 1.8 (1.1) Current smoker % Medical history Myocardial infarction % Angina % Peripheral vascular disease % TIA or stroke % 11 9 Type 1 diabetes % 2 3 Type 2 diabetes % 6 6 Current treatment Beta-blocker % Calcium antagonist % Cholesterol lowering drug % Antiplatelet agent % HDL high density lipoprotein; LDL low density lipoprotein; TIA transient ischemic attack. A total of 617 patients were randomized in this study. Characteristics of the participants at entry to the study are given in Table 1. The mean age of participants was 61 years, 82% were men, and 16% were current smokers. The average BP at entry was 133/79 mm Hg, and the average total cholesterol concentration was 6.1 mmol/l. Sixty-eight percent of patients had a history of coronary heart disease, 20% had a history of peripheral vascular disease, and 10% had a history of ischemic stroke or TIA. Forty-three percent of patients were receiving a beta-blocker, 25% a calcium antagonist, 29% a cholesterol lowering drug and 81% an antiplatelet agent. A total of 744 potentially eligible patients entered the prerandomization run-in period, of which 617 patients (83%) were randomized. Of the 17% who withdrew before randomization, the reasons for withdrawal were ineligibility in 7%, suspected adverse reaction in 7% and patient preference in 3%. Three hundred eight patients were assigned treatment with ramipril, and 309 were assigned placebo. Of those randomized to ramipril, 83% received 10 mg daily and 17% received 5 mg daily. At the year 4 examination, 72% of patients who had been assigned ramipril and 75% of patients who had been assigned placebo were still taking study treatment. By the same time, 3% of patients who had been assigned ramipril and 7% of patients who had been Table 2. Systolic and Diastolic Blood Pressure in Randomized Groups at Baseline and at Follow-up Baseline Year 2 Year 4 p Value* Systolic blood pressure (mm Hg) Ramipril Placebo Diastolic blood pressure (mm Hg) Ramipril Placebo *Two-sided p value for interaction between treatment group and time of measurement. assigned placebo had begun nonstudy treatment with an ACE inhibitor. The main reasons for stopping randomized treatment were suspected adverse drug reactions (10% in the ramipril group, 1% in the placebo group) and patient preference (7% in both groups). Data from carotid B-mode ultrasound examinations were available from all randomized patients at baseline and between 88% and 95% of patients during follow-up. Data from M-mode echocardiography examinations were available from 94% of patients at baseline and between 77% and 81% of patients during follow-up. Data on vital status at the end of follow-up were available for all but one patient (assigned placebo). The average duration of total follow-up was 4.7 years. On average overall follow-up, there was a 6 mm Hg reduction in systolic BP anda4mmhgreduction in diastolic BP in the ramipril group compared with the placebo group (both p ) (Table 2). The sizes of the reductions in BP at year 2 and year 4 were similar. There was no significant difference in the change in common carotid far wall thickness from baseline to follow-up between ramipril and placebo groups (0.01 mm, p 0.58) nor was there any difference between groups in the change in carotid plaque score (p 0.93) (Table 3 and Fig. 1). There was a small increase in the common carotid artery lumen diameter in the placebo group compared with the ramipril group during follow-up (0.06 mm, p 0.02). After adjustment for the expected effects of these differences in lumen diameter on carotid artery wall thickness (assuming conservation of wall mass and an inverse relationship between change in radius and change in wall thickness), there was still no evidence of any effect of study treatment on far wall thickness (p 0.98). By year 4, there was a 3.8 g/m 2 reduction in LV mass index in the ramipril group compared with the placebo group (p 0.04). This change was associated with a small increase in LV end diastolic dimension in the placebo group compared with the ramipril group (p 0.004). The differences between groups in LV mass index and end diastolic dimension were similar at years 2 and 4. During follow-up, 41 patients died (16 in the ramipril group and 25 in the placebo group, p 0.17), and 279 people in the ramipril group and 289 in the placebo group were admitted to the hospital at least once (p 0.18) (Table 4). For the combined end point of death from cardiovascular disease or hospital admission for MI, unstable angina, CHF

4 JACC Vol. 36, No. 2, 2000 August 2000: MacMahon et al. Ramipril and Atherosclerosis 441 Table 3. Common Carotid Artery and Left Ventricular Measurements in Randomized Groups at Baseline and Follow-up Baseline Year 2 Year 4 p Value* Common Carotid Arteries Far wall thickness (mm) Ramipril Placebo Plaque score (mm) Ramipril Placebo Lumen diameter (mm) Ramipril Placebo Left Ventricle Mass index (kg/m 2 ) Ramipril Placebo End diastolic dimension (mm) Ramipril Placebo Mean wall thickness (mm) Ramipril Placebo *Two-sided p value for interaction between treatment group and time of measurement. or stroke, there was no evidence of a difference in the frequency of this outcome in the ramipril and placebo groups (relative risk 0.95), but the confidence interval was wide ( ). There were nonsignificant trends toward fewer deaths from cardiovascular disease in the ramipril group (relative risk 0.43, 95% confidence interval ) and fewer major coronary events (death from coronary disease or nonfatal MI) in the ramipril group (relative risk 0.66, 95% confidence interval ). DISCUSSION This randomized trial is the largest completed study of the effects of any ACE inhibitor on atherosclerosis in any patient population. Its results provide no evidence of an effect of long-term treatment with ramipril on carotid atherosclerosis among patients with coronary or other occlusive vascular disease. There was more than 80% power to detect a difference of 0.05 mm in carotid wall thickness between patients assigned ramipril or placebo, so it is unlikely that any real effect of treatment greater than about 5% would have gone undetected. However, the study would not have been able to reliably detect smaller effects of treatment on carotid atherosclerosis. With regard to the sensitivity of the study to detect plausible treatment effects, it is noteworthy that in a trial of similar size and duration using the same ultrasound methods, cholesterol lowering with an 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor was shown to produce a clear reduction in the progression of carotid atherosclerosis among patients with coronary heart disease (9). This study recorded too few major cardiovascular events to provide reliable evidence Figure 1. Common carotid artery wall thickness (A) and carotid plaque score (B) in placebo and ramipril groups at baseline and at follow-up. about moderate effects of treatment on such outcomes; however, the 95% confidence intervals for the estimates of treatment effect were consistent with those effects observed in the HOPE study (3) and others (1,2). The absence of any demonstrable effect of ramipril on carotid atherosclerosis in this study is consistent with the findings of the only other major randomized controlled trial that has reported effects of an ACE inhibitor on atherosclerosis. In the atherosclerosis substudy of the QUIET (Quinapril Ischemic Events Trial) trial, 453 patients with coronary heart disease were randomized to receive quinapril or placebo, and after three years there was no evidence of any effect of study treatment on coronary atherosclerosis assessed by angiography (11). The only other moderate-tolarge-scale studies to have investigated the effects of these agents on the coronary arteries are those trials of ACE inhibitors in patients undergoing coronary angioplasty, which showed no effect of treatment on the rate of restenosis (12 14). These negative trial results in humans contrast with the evidence of marked anti-atherosclerotic and antiproliferative effects of very high-dose ACE inhibition in studies of diet- or endothelial injury induced atherosclerosis in animals (5 8). These observations raise doubts about the value of some animal models of atherosclerosis for the

5 442 MacMahon et al. JACC Vol. 36, No. 2, 2000 Ramipril and Atherosclerosis August 2000: Table 4. Fatal and Nonfatal Cardiovascular Events During Follow-up Ramipril (n 308) Placebo (n 309) Relative Risk 95% Confidence Interval Fatal events Coronary heart disease (0.17, 1.14) Other cardiovascular (0.09, 2.60) All cardiovascular (0.19, 1.03) All noncardiovascular (0.42, 3.19) Total deaths (0.34, 1.20) Nonfatal events* Myocardial infarction (0.49, 1.80) Unstable angina (0.71, 1.65) Stroke (0.48, 5.75) Congestive heart failure (0.29, 2.09) Combined outcomes Death from coronary heart disease or (0.39, 1.14) nonfatal myocardial infarction Death from cardiovascular disease or hospital admission for major cardiovascular event (0.69, 1.31) *Requiring hospital admission; including myocardial infarction, unstable angina, congestive heart failure or stroke. investigation of drug effects and of the use of drug doses in experimental studies so far outside the range of that typically used in humans. The results of this trial suggest that mechanisms other than reduced progression of atherosclerosis are likely to mediate the main effects of ACE inhibitors on the risk of coronary events and other serious cardiovascular outcomes. The results of this study suggest that reduced BP and LV mass among patients treated with an ACE inhibitor may be more relevant. Both these outcomes have been shown to predict coronary disease and other cardiovascular events in various populations (15 18). Similar effects of ACE inhibitors have previously been observed in trials in hypertensive patients with LV hypertrophy (19,20). Whether such effects on BP and LV mass account for all of the reduction in coronary events observed in trials of ACE inhibitors is uncertain. From epidemiological data (15) it can be estimated that the reduction in BP observed in this study could account for as much as a 15% reduction in coronary events (i.e., about three-quarters of the reduction in coronary events observed in the previous trials of ACE inhibitors [1 3]). However, it is also possible that there are other mechanisms by which ACE inhibitors might alter coronary risk, including reversal of endothelial dysfunction (21), leading, perhaps, to increased plaque stability and reduced risk of plaque rupture. Further research on the mechanisms of benefit from ACE inhibition is required. In summary, the results of this trial provide no evidence of any substantial effect of ACE inhibitors on carotid atherosclerosis. However, the results extend to nonhypertensive patients the evidence that treatment with these agents not only reduces BP but also reduces LV mass. Changes in these or other mechanisms, rather than changes in atherosclerosis, appear more likely to mediate the beneficial effects of ACE inhibitors on coronary events and other serious cardiovascular outcomes observed in randomized controlled trials. Whether other BP-lowering drugs have effects on atherosclerotic progression is still somewhat uncertain. Two large studies comparing the effects of calcium antagonist- and diuretic-based therapy in hypertensive patients have provided weak evidence of reduced atherosclerotic progression among patients assigned the calcium antagonist (22,23). The clinical consequences of any such differences between the effects of BP-lowering drugs are uncertain, but these should be determined by the ongoing large-scale trials comparing the effects of various agents on cardiovascular disease mortality and morbidity (24). Acknowledgments The authors would like to thank Colleen Ciobo, Suzanne Flett, Gillian Whalley and Dr. Mike Bao for performing all ultrasound examinations and measurements; Janet Brown, Loretta Bush, Jacqui Elliott, Kathy Green, Jo Hinge, Jo Holland, Carol O Toole, Lynette Pearce, Alison Randall and Philippa Wright for managing the study clinics; Drs. Sarah Aly, Robert Doughty, Andrew Hamer, Tom Hyde, Heather King, Pauline McDowell, Krishnan Ramanathan and Miles Williams for assisting with patient management; Joanna Broad for providing statistical advice and Brett Cowan for providing advice about the analysis of carotid wall thickness adjusted for changes in lumen diameter; Robyn Beckerleg for providing administrative support; Amanda Milne for supervising data processing; Alan Mc- Culloch for being the study programmer and Professor Ian Reid for chairing the study data monitoring committee. Reprint requests and correspondence: Dr. Stephen MacMahon, Institute for International Health, The University of Sydney, PO Box 1225, Crows Nest, Sydney NSW 1585, Australia.

6 JACC Vol. 36, No. 2, 2000 August 2000: MacMahon et al. Ramipril and Atherosclerosis 443 REFERENCES 1. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensinconverting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90: Garg R, Yusuf S. Overview of randomized trials of angiotensinconverting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273: The HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of the angiotensin converting enzyme-inhibitor, ramipril, on cardiovascular death, myocardial infarction and stroke in high-risk patients. N Engl J Med 2000;342: Dzau VJ. Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens 1994;12 Suppl:S3 S Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15: Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15: Kuhn H, Hefti F, Hosang M, et al. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245: Campbell JH, Fennessy P, Campbell GR. Effect of perindopril on the development of atherosclerosis in the cholesterol-fed rabbit. Clin Exper Pharmacol Physiol 1992;19: MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average or below average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID Atherosclerosis Substudy. Circulation 1998;16: Gamble G, Beaumont B, Smith H, et al. B-mode ultrasound images of the carotid artery wall: correlation of ultrasound with histological measurements. Atherosclerosis 1993;102: Cashin-Hemphill L, Holmvang G, Chan R, Pitt B, Dinsmore R, Lees R. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Coronary artery disease. Am J Cardiol 1999;83: MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor, cilazapril, prevent restenosis after percutaneous transluminal angioplasty? Circulation 1992;86: Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Card 1995;25: Desmet W, Vrolix M, de Scheerder I, Van Lierde J, Willems JL, Piessens J. Angiotensin converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after angioplasty. Circulation 1994;89: MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335: Flack J, Neaton J, Grimm R, et al. Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995;92: Levy D, Garrison R, Savage D, Kannel W, Castelli W. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322: Bolognese L, Dellavese P, Rossi L, Sarasso G, Bonfo AS, Scianaro MC. Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and on vessel coronary artery disease. Am J Cardiol 1994;73: Dahlof D. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992;5: Schmeider AM. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. J Am Med Assoc 1996;275: Mancini GB, Henr GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94: Borhani N, Mercuri M, Borhani P, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996;276: Zanchetti A, Agabiti-Rosei E, Dal Palu C, Lenetti G, Magnani B, Pessina A, for the VHAS Investigators. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998;16: World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood pressure lowering treatments. J Hypertens 1998;16:

Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease

Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease European Heart Journal (2003) 24, 475 484 Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease PROGRESS Collaborative Group 1*

More information

Data Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition

Data Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition Vascular Bi o l o g y Work i n g Gro u p c/o Medical Education Consultants, In c. 25 Sy l van Road South, We s t p o rt, CT 06880 Chairman: Carl J. Pepine, MD Professor and Chief Division of Cardiovascular

More information

1048 JACC Vol. 27, No. 5 April 1996:

1048 JACC Vol. 27, No. 5 April 1996: 1048 JACC Vol. 27, No. 5 SPECIAL ARTICLE Ongoing Clinical Trials of Angiotensin-Converting Enzyme Inhibitors for Treatment of Coronary Artery Disease in Patients With Preserved Left Ventricular Function

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Experimental and epidemiological data suggest that activation

Experimental and epidemiological data suggest that activation Clinical Investigation and Reports Effects of Ramipril and Vitamin E on Atherosclerosis The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) Eva M.

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi

In the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.

More information

Clinical Trial Synopsis TL-OPI-518, NCT#

Clinical Trial Synopsis TL-OPI-518, NCT# Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride

More information

The Angiotensin-converting Enzyme Inhibition Post Revascularization

The Angiotensin-converting Enzyme Inhibition Post Revascularization Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00634-8 CLINICAL

More information

Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease

Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Iana I. Simova, MD; Stefan V. Denchev, PhD; Simeon I. Dimitrov, PhD Clinic of Cardiology, University Hospital Alexandrovska,

More information

Clinical Trial Synopsis TL-OPI-516, NCT#

Clinical Trial Synopsis TL-OPI-516, NCT# Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus

More information

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.

Journal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20. Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL

More information

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply. WHI Form - Report of Cardiovascular Outcome Ver. 6. COMMENTS To be completed by Physician Adjudicator Date Completed: - - (M/D/Y) Adjudicator Code: OMB# 095-044 Exp: 4/06 -Affix label here- Clinical Center/ID:

More information

Prevalence of left ventricular hypertrophy in a hypertensive population

Prevalence of left ventricular hypertrophy in a hypertensive population European Heart Journal (1996) 17, 143-149 Prevalence of left ventricular hypertrophy in a hypertensive population J. Tingleff, M. Munch, T. J. Jakobsen, C. Torp-Pedersen, M. E. Olsen, K. H. Jensen, T.

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

LIST OF ABBREVIATIONS

LIST OF ABBREVIATIONS Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,

More information

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without

More information

Low fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease

Low fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease (2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk

More information

The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction

The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.

More information

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental

More information

Journal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.

Journal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20. Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early

More information

Citation for published version (APA): Terpstra, W. F. (2003). Beyond blood pressure monitoring Groningen: s.n.

Citation for published version (APA): Terpstra, W. F. (2003). Beyond blood pressure monitoring Groningen: s.n. University of Groningen Beyond blood pressure monitoring Terpstra, Willem Fopke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION

VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with

More information

Journal of the American College of Cardiology Vol. 46, No. 8, by the American College of Cardiology Foundation ISSN /05/$30.

Journal of the American College of Cardiology Vol. 46, No. 8, by the American College of Cardiology Foundation ISSN /05/$30. Journal of the American College of Cardiology Vol. 46, No. 8, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.070

More information

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension. 2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature

More information

Journal of the American College of Cardiology Vol. 41, No. 6, by the American College of Cardiology Foundation ISSN /03/$30.

Journal of the American College of Cardiology Vol. 41, No. 6, by the American College of Cardiology Foundation ISSN /03/$30. Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(03)00052-4

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

PRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING M-MODE ECHOCARDIOGRAPHY

PRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING M-MODE ECHOCARDIOGRAPHY Malaysian Journal of Medical Sciences, Vol. 9, No. 1, January 22 (28-33) ORIGINAL ARTICLE PRELIMINARY STUDIES OF LEFT VENTRICULAR WALL THICKNESS AND MASS OF NORMOTENSIVE AND HYPERTENSIVE SUBJECTS USING

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,

More information

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM REVIEW DATE REVIEWER'S ID HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM : DISCHARGE DATE: RECORDS FROM: Hospitalization ER Please check all that may apply: Myocardial Infarction Pages 2, 3,

More information

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

More information

Improving Medical Statistics and Interpretation of Clinical Trials

Improving Medical Statistics and Interpretation of Clinical Trials Improving Medical Statistics and Interpretation of Clinical Trials 1 ALLHAT Trial & ALLHAT Meta-Analysis Critique Table of Contents ALLHAT Trial Critique- Overview p 2-4 Critique Of The Flawed Meta-Analysis

More information

Slide notes: References:

Slide notes: References: 1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory

More information

Preventing the cardiovascular complications of hypertension

Preventing the cardiovascular complications of hypertension European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig

More information

Coronary artery disease (CAD) risk factors

Coronary artery disease (CAD) risk factors Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes

More information

National Medicines Information Centre

National Medicines Information Centre National Medicines Information Centre VOLUME 8 NUMBER 6 2002 ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 E-Mail: nmic@stjames.ie If you would like to receive NMIC publications

More information

Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri

Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri Original Research Article Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri P. Sasikumar * Department of General Medicine, Govt.

More information

Influence of Baseline Lipids on Effectiveness of Pravastatin in the CARE Trial

Influence of Baseline Lipids on Effectiveness of Pravastatin in the CARE Trial JACC Vol. 33, No. 1 January 1999:125 30 125 Influence of Baseline Lipids on Effectiveness of Pravastatin in the CARE Trial MARC A. PFEFFER, MD, PHD, FACC, FRANK M. SACKS, MD, LEMUEL A. MOYÉ, MD, PHD,*

More information

The target blood pressure in patients with diabetes is <130 mm Hg

The target blood pressure in patients with diabetes is <130 mm Hg Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is

More information

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients 1/5 This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

TREATMENT AND COMPLICAtions

TREATMENT AND COMPLICAtions ORIGINAL CONTRIBUTION JAMA-EXPRESS Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic The Antihypertensive and

More information

Hypertension is a major risk factor for morbidity

Hypertension is a major risk factor for morbidity O r i g i n a l P a p e r Long-Term Effects of a Losartan- Compared With an Atenolol-Based Treatment Regimen on Carotid Artery Plaque Development in Hypertensive Patients With Left Ventricular Hypertrophy:

More information

Coronary Artery Disease: Revascularization (Teacher s Guide)

Coronary Artery Disease: Revascularization (Teacher s Guide) Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention

More information

Test-Retest Reproducibility of the Wideband External Pulse Device

Test-Retest Reproducibility of the Wideband External Pulse Device Test-Retest Reproducibility of the Wideband External Pulse Device Cara A. Wasywich, FRACP Warwick Bagg, MD Gillian Whalley, MSc James Aoina, BSc Helen Walsh, BSc Greg Gamble, MSc Andrew Lowe, PhD Nigel

More information

Therapeutic Targets and Interventions

Therapeutic Targets and Interventions Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium

More information

BLOOD PRESSURE-LOWERING TREATMENT

BLOOD PRESSURE-LOWERING TREATMENT BLOOD PRESSURE-LOWERING TRIALS NUMBER OF PARTICIPANTS NUMBER OF PERCENTAGE OF MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 69,473 28,008 40.3% 70.2 3.2 3/5 (60%) APPENDIX 2 1 BLOOD PRESSURE-LOWERING

More information

T. Suithichaiyakul Cardiomed Chula

T. Suithichaiyakul Cardiomed Chula T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial

More information

Presented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer

Presented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer Presented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer Patients Randomized by Country 187 UK n=187 Norway n=425 Finland

More information

LDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC

LDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive

More information

Lowering blood pressure in 2003

Lowering blood pressure in 2003 UPDATE CLINICAL UPDATE Lowering blood pressure in 2003 John P Chalmers and Leonard F Arnolda Institute for International Health, University of Sydney, Sydney, NSW. John P Chalmers, MD, FRACP, Professor

More information

Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril JAMA. 2005;293:

Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril JAMA. 2005;293: ORIGINAL CONTRIBUTION Outcomes in Hypertensive and Patients Treated With, Amlodipine, and Lisinopril Jackson T. Wright, Jr, MD, PhD J. Kay Dunn, PhD Jeffrey A. Cutler, MD Barry R. Davis, MD, PhD William

More information

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular

More information

Blood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension

Blood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension 525 Blood Pressure Lowering Efficacy of Perindopril/ Indapamide Fixed Dose Combination in Uncontrolled Hypertension PHIMDA Kriangsak 1* and CHOTNOPARATPAT Paiboon 2 1 Diabetes and Hypertension Clinic,

More information

How to detect early atherosclerosis ; focusing on techniques

How to detect early atherosclerosis ; focusing on techniques How to detect early atherosclerosis ; focusing on techniques Jang-Ho Bae, MD., PhD. Heart Center Konyang University Hospital Daejeon city, S. Korea Surrogates for Atherosclerosis Measures of endothelial

More information

ORIGINAL INVESTIGATION. Calcium Antagonists and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study

ORIGINAL INVESTIGATION. Calcium Antagonists and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study ORIGINAL INVESTIGATION s and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study Vivian M. Abascal, MD; Martin G. Larson, ScD; Jane C. Evans, MPH; Ana T. Blohm, BA; Kim Poli,

More information

Heart Failure with Preserved Ejection Fraction: Mechanisms and Management

Heart Failure with Preserved Ejection Fraction: Mechanisms and Management Heart Failure with Preserved Ejection Fraction: Mechanisms and Management Jay N. Cohn, M.D. Professor of Medicine Director, Rasmussen Center for Cardiovascular Disease Prevention University of Minnesota

More information

Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease

Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease ...SYMPOSIUM PROCEEDINGS... Changes in Blood Pressure and Vascular Physiology: Markers for Cardiovascular Disease Based on a presentation by Joseph L. Izzo, Jr., MD Presentation Summary Changes in systolic

More information

Other views (commentary on "Antihypertensive therapy: beta-blockers and diuretics")

Other views (commentary on Antihypertensive therapy: beta-blockers and diuretics) BUMC Proceedings 2000;13:131-134 Other views (commentary on "Antihypertensive therapy: beta-blockers and diuretics") r. Messerli has advanced what, on the surface, appears to be a convincing argument that

More information

10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor

10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor Lecture 9 Cardiovascular Health 1 Lecture 9 1. Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor 1 The Heart Muscular Pump The Heart Receives blood low pressure then increases the pressure

More information

Data Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.

Data Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease. 1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association

More information

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular

More information

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for

More information

Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study

Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study Andre Lamy, MD, MHSc; Salim Yusuf, DPhil; Janice Pogue, MSc; Amiram Gafni,

More information

COURAGE to Leave Diseased Arteries Alone

COURAGE to Leave Diseased Arteries Alone COURAGE to Leave Diseased Arteries Alone Spencer King MD MACC, FSCAI St. Joseph s s Heart and Vascular Institute Professor of Medicine Emeritus Emory Univ. Atlanta, USA Conflict: I am an Interventionalist

More information

Protecting the heart and kidney: implications from the SHARP trial

Protecting the heart and kidney: implications from the SHARP trial Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016 Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss

More information

Treatment to reduce cardiovascular risk: multifactorial management

Treatment to reduce cardiovascular risk: multifactorial management Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University

More information

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology Cardiac evaluation for the noncardiac patient Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology Objectives! Review ACC / AHA guidelines as updated for 2009! Discuss new recommendations

More information

VIEWPOINT. Journal of the American College of Cardiology Vol. 37, No. 5, by the American College of Cardiology ISSN /01/$20.

VIEWPOINT. Journal of the American College of Cardiology Vol. 37, No. 5, by the American College of Cardiology ISSN /01/$20. Journal of the American College of Cardiology Vol. 37, No. 5, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01161-5 VIEWPOINT

More information

Management of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB

Management of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB Management of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB Increasing stroke numbers in New Zealand an 'epidemic' says leading AUT

More information

The problem of uncontrolled hypertension

The problem of uncontrolled hypertension (2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands

More information

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015 Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have

More information

Metoprolol Succinate SelokenZOC

Metoprolol Succinate SelokenZOC Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic

More information

The effective treatment of hypertension is surprisingly. Unsolved Problems in Treating Hypertension. Rationale for New Approaches. Michael A.

The effective treatment of hypertension is surprisingly. Unsolved Problems in Treating Hypertension. Rationale for New Approaches. Michael A. AJH 1998;11:145S 149S Unsolved Problems in Treating Hypertension Rationale for New Approaches Michael A. Weber Two major problems continue to challenge hypertension experts and clinical practitioners.

More information

Should beta blockers remain first-line drugs for hypertension?

Should beta blockers remain first-line drugs for hypertension? 1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,

More information

Trials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1

Trials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1 Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings

More information

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors Lecture 8 Cardiovascular Health 1 Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors 1 Human Health: What s Killing Us? Health in America Health is the U.S Average life

More information

Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol

Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol The Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study Peter M. Okin, MD; Richard B. Devereux,

More information

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled Articles MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebocontrolled trial Heart Protection Study Collaborative Group* Summary Background

More information

Large therapeutic studies in elderly patients with hypertension

Large therapeutic studies in elderly patients with hypertension (2002) 16 (Suppl 1), S38 S43 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Large therapeutic studies in elderly patients with hypertension Centro Clinico Profesional

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?

Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure

More information

International Journal of Pharma and Bio Sciences

International Journal of Pharma and Bio Sciences International Journal of Pharma and Bio Sciences RESEARCH ARTICLE ANGIOTENSIN CONVERTING ENZYME LEVELS IN ISCHEMIC CEREBROVASCULAR DISORDERS: A CASE-CONTROL PILOT STUDY IN NORTH INDIAN POPULATION JASPREET

More information

Landmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549

Landmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549 2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:

More information

Environmental. Vascular / Tissue. Metabolics

Environmental. Vascular / Tissue. Metabolics Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood

More information

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk

More information

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE

03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no

More information

Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial Infarction

Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial Infarction Effects of Carvedilol on Left Ventricular Remodeling After Acute Myocardial Infarction The CAPRICORN Echo Substudy Robert N. Doughty, MD, MRCP, FRACP; Gillian A. Whalley, MHSc, DMU; Helen A. Walsh, BSc;

More information

Managing HTN in the Elderly: How Low to Go

Managing HTN in the Elderly: How Low to Go Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Blood Pressure Targets: Where are We Now?

Blood Pressure Targets: Where are We Now? Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy

More information

Dr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra

Dr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra Dr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra Beta-blockers were used in several longterm morbidity and trials in the treatment of hypertension, either alone or in comparison

More information

Clinical cases with Coversyl 10 mg

Clinical cases with Coversyl 10 mg Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive

More information